MoneyWorks4Me

Shilpa Medicare informs about disclosure

15 Mar 2025 Evaluate
Shilpa Medicare has informed that United States Food and Drugs Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences, located at Raichur from March 10-14, 2025. The inspection was closed with ZERO observations. This is second consecutive ZERO 483 inspection from USFDA at this site.

The above information is a part of company’s filings submitted to BSE.



Shilpa Medicare Share Price

821.90 14.50 (1.80%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: